GO:0035634Ontology (GO BP)GO biological process · ~8 member genes
Q-omics provides the Response to stilbenoid (GO:0035634) pathway profile, scoring each patient from the combined activity of its roughly 8 member genes. Pathway activity is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, the pathway is differentially active in 10, with the highest sampling consensus in THCA. Additionally, pathway RNA activity shows 27,081 significant cross-omics associations, again with the highest sampling consensus in THCA. Together, these results highlight PAAD, and THCA as cancer lineages where the pathway shows reproducible signals across outcome, tissue activity, and molecular association analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns. Pathway-against-pathway and pathway-against-mutation comparisons are not available for ontology entities.
Survival associations
This table summarizes Response to stilbenoid survival associations by molecular data type. RNA-level pathway activity shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each layer.
This table ranks reproducible pathway activity–survival associations across cancer types. High Response to stilbenoid activity shows favorable associations in PAAD, ACC, LUAD and MESO, but unfavorable associations in SCLC and SKCM. In the PAAD Kaplan–Meier curve the low-activity group declines faster, consistent with the favorable association (log-rank p = .006). PAAD ranks highest by sampling consensus for Response to stilbenoid.
This table summarizes Response to stilbenoid tumor–normal activity differences by data type. RNA-level activity shows significant tumor–normal differences in 10 cancer types, while mass-spec protein activity shows differences in 5. The strongest signals are in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal activity differences for the pathway. A positive fold-change indicates higher activity in tumor tissue. The pathway shows higher tumor activity across COAD and lower tumor activity in THCA, LIHC, LUAD, KICH and BRCA. In the THCA box plot, normal samples show higher pathway activity than tumor samples (log2 FC = −0.162, t-test p < 0.001).
This table shows molecular features associated with Response to stilbenoid pathway activity in patient tissues and cancer cell lines. In patient samples, pathway activity is most strongly linked to RNA and protein features, with the largest associated set in THCA. In cancer cell lines, RNA-expression features and functional dependencies dominate, with the largest set in LUNG_SCLC.
